Thyroid carcinoma accounts for the majority of deaths from endocrine cancers. Although effective therapies exist for well differentiated tumors, the treatment options for poorly differentiated and anaplastic tumors are much less effective. In the present study we demonstrate that the thyroglobulin (Tg) promoter can be used to direct specific expression of either luciferase or thymidine kinase in thyroid cancer cells. Furthermore, using a putative enhancer element for the Tg gene, the activity of the Tg promoter in and its specificity for thyroid cells were enhanced. In transient transfectants or in stably transfected thyroid carcinoma cells, treatment with the histone deacetylase inhibitors, depsipeptide (FR9012228) and sodium butyrate, alone or in combination with 8-bromo-cAMP, resulted in further enhancement. In experiments in which the herpes simplex virus thymidine kinase (HSV-TK) gene was driven by the Tg promoter and the putative enhancer, HSV-TK expression and ganciclovir sensitivity were augmented. Similar results were obtained in two cell lines derived from a follicular thyroid carcinoma and in two anaplastic thyroid carcinoma cell lines. In summary, we report the construction of a suicide HSV-TK vector with preferential toxicity for thyroid cells. The results in anaplastic thyroid carcinoma cells suggest that it may be of use in the full spectrum of thyroid malignancies. (J Clin Endocrinol Metab 86: 834 -840, 2001) 
T HYROID CARCINOMA is the most common endocrine malignancy, accounting for the majority of deaths from endocrine cancers (1) . Each year in the United States, approximately 14,000 new cases of thyroid carcinoma are diagnosed, and 1,200 patients die from this disease (2) . Conventional therapy consists of surgical resection and radioiodine ( 131 I) therapy (3, 4) . However, for poorly differentiated thyroid carcinomas as well as anaplastic carcinomas, which do not concentrate iodine, 131 I therapy is ineffective (1, 5) . In these patients the therapeutic options are few and largely unsuccessful. Palliative or debulking surgery, external radiation, and chemotherapy have all been tried, with limited success (6 -11) . Among experimental options, restoration of iodine trapping has been pursued, without convincing efficacy (12) (13) (14) (15) (16) .
Suicide gene therapy strategies exploit genes that are expressed preferentially or exclusively in tumors to target therapy. Endocrine cancers as a group and thyroid cancers in particular possess numerous genes whose expression is very restricted or specific. For thyrocytes and well differentiated thyroid cancers, specific genes include thyroglobulin (Tg), the Na ϩ /I Ϫ symporter (NIS), thyroid peroxidase, iodothyronine 5Ј-deiodinase, and the TSH receptor. Braiden et al. showed the usefulness of Tg promoters as a transcriptionally targeted gene therapy (17) . The present studies were designed to enhance the activity of a thyroid-specific Tg promoter in transcriptionally targeted gene therapy.
Materials and Methods

Cell lines and culture conditions
We used a total of nine cell lines: two follicular thyroid carcinomas (FTC 133 and FTC 236), two anaplastic thyroid carcinomas (KAT-4 and SW-1736), an adrenocortical carcinoma (H295) (18) , a colon carcinoma (SW620), a renal cell carcinoma (A498), a breast carcinoma (MCF7), and a hepatocarcinoma (HepG2). FTC 133 and FTC 236 were derived from cultures obtained from the primary tumor (FTC 133) and a nodal metastasis (FTC 236) of a follicular thyroid carcinoma. The anaplastic thyroid carcinoma cell lines were derived from primary cultures of human anaplastic thyroid carcinoma tumors. SW-1736 was developed by Drs. Leibowitz and McCombs III at the Scott and White Memorial Hospital (Temple, TX) in 1977 and was provided by Nils-Erik Heldin (Uppsala University, Uppsala, Sweden). KAT-4 was developed and maintained in the laboratory of Kenneth Ain (University of Kentucky). FTC236, FTC133, KAT-4, SW-1736, and SW620 were maintained in RPMI 1640 with glutamine medium supplemented with 10% FCS at 37 C in a 5% CO 2 incubator. H295 cells were maintained in RPMI, with the addition of HEPES, ITS (insulin, transferrin, selenium), and 2% serum. A498, MCF7, and HepG2 cells were maintained in Iscove's MEM supplemented with 10% serum. Although the serum used may contain TSH or TSH-like activity, we observed that adding supplemental TSH had no effect on the growth rate or plating efficiency of these cell lines.
RT-PCR
Total ribonucleic acid (RNA) was extracted using RNA STAT-60 (Tel-Test, Friendswood, TX). RT-PCR was performed as previously described (19) . The primers used for amplification of endogenous Tg gene were: Tg 5Ј (sense), 5354 GAAATCGTCGTCTTCTCCAC 5374 ; and Tg 3Ј (antisense), 5565 CTGTCAGCACAGTGGCAATA 5584 . RNA from a normal thyroid was amplified in every experiment and included in every gel. Thus, in every experiment the reaction conditions were internally controlled, and in every gel a reference standard was included.
Construction of reporter plasmids
The promoter of the Tg gene was isolated using the PCR and DNA from FTC 236 cells. Primers used were: 5Ј (sense), Ϫ500 GAGCTCTAA-GAGGTTGTTAGAG
Ϫ479
; and 3Ј (antisense), ϩ40 TTTCCTGGCCCTTC-CTGGGAGGAA ϩ17 . The amplified fragment was subcloned into the pCRII TA vector (Invitrogen, San Diego, CA), and its sequence was confirmed. After digestion with KpnI and XhoI, the 540-bp promoter fragment was ligated to the pGL3-B luciferase vector (Promega Corp., Madison, WI). This construct was designated Tg promoter-Luc. In addition, the herpes simplex virus thymidine kinase (HSV-TK) minimum promoter was excised by digesting pRL-TK (Promega Corp.) with HindIII and BglII; this was subcloned into pGL3-B and designated TKLuc. TK-Luc was used as the positive control.
The enhancer element of the Tg gene was amplified using the PCR and the following primers: 5Ј (sense), CGGGGTACC Ϫ2698 GT-TCTCACGAGCTCAGTGGAG Ϫ2677 ; and 3Ј (antisense), CGGAC-TAGT Ϫ2172 CCCATTGCCCTAAAATGCATGC Ϫ2193 . KpnI (sense) and SpeI (antisense) restriction sites flanked the Tg enhancer sequence. The amplified fragment was inserted into the Tg promoter-Luc plasmiddigested with KpnI and SpeI. This construct was designated Tg enhancer/promoter-Luc.
To construct Tg enhancer/promoter-TK, we isolated the TK gene by digesting pGL3-TK containing the coding region of the HSV-TK gene with XhoI and XbaI. The TK-coding region was then inserted into Tg enhancer/promoter-Luc that had been digested with XhoI and XbaI to release the luciferase gene. This construct was designated Tg enhancer/ promoter-TK. In addition, to generate a construct that could be used to establish stable transfectants, the Tg enhancer/promoter-TK-coding region was subcloned into pcDNA3.1 The total sequence of the cytomegalovirus promoter was removed by using MluI and HindIII. This construct was designated Tg enhancer/promoter-TK-Neo. Finally, the HSV-TK minimum promoter was excised by digesting pRL-TK (Promega Corp.) with HindIII and BglII; this was subcloned into pGL3-B and designated TK-TK. The vectors used in this study are shown in Fig. 1 .
Transfections and luciferase assays
Transient transfections used a liposome-mediated method. Because of their slow growth rate, 2 ϫ 10 5 H295 cells were plated in each well of a 24-well plate 2 days before transfection; for all other cell lines, 3-4 ϫ 10 4 cells were plated 24 h before transfection. Plasmid DNA (0.5 g) and 4.5 L TransFast (Promega Corp.) mixed with 200 L medium were added to each well. After incubating for 1 h in the above mixtures, cells were cultured in the presence or absence of various agents for 2 days. The agents used and their concentrations were as follows: 1) 0.3 mmol/L 8-bromo-cAMP (8-Br-cAMP), 2) 20 mol/L forskolin, 3) 1.2 mmol/L phenylbutyrate, 4) 2 mmol/L sodium butyrate, and 5) 1 ng/mL depsipeptide (FR901228). After harvesting, the total protein concentration was measured by protein assay (Bio-Rad Laboratories, Inc., Richmond, CA). Firefly luciferase activity was assessed using the Luciferase Assay System (Promega Corp.) and was normalized to protein. All transfections were performed in triplicate. In all experiments TK-Luc and pGL3-B were used as positive and negative controls, respectively. The result with the TK-Luc vector was assigned a value of 100%, and all other values were expressed relative to this as relative luciferase units.
Stable transfection of thyroid cancer cells with the Tg enhancer/ promoter-TK-Neo vector employed TransFast. After 3 weeks in medium containing 300 g/mL G418, stable transfectants were isolated.
Immunoblot analysis
Stable transfectants were scraped into cell lysis buffer containing 10 mmol/L Tris (pH 7.4), 150 mmol/L NaCl, 1% Nonidet P-40, 1 mmol/L ethylenediamine tetraacetate, 20 g/mL aprotinin, and 100 g protein was separated on a 10% SDS-PAGE gel. Electroblotting to Immobilon P transfer membrane (Millipore Corp., Bedford, MA) was performed, and nonspecific protein binding was blocked using 10% milk in TNE buffer [2 mmol/L Tris (pH 7.4), 2 mmol/L NaCl, 1 mmol/L ethylenediamine tetraacetate, and 0.15% Tween-20] for 1 h. The membrane was incubated for 1 h with a rabbit polyclonal antibody for HSV-TK (provided by Dr. William C. Summers, Yale University, New Haven, CT), diluted 1:1000 in 5% milk, and 0.02% sodium azide in TNE. After washing, antirabbit Ig horseradish peroxidase-linked secondary antibody (Amersham Pharmacia Biotech, Arlington Heights, IL) was added for 1 h. After washing, the membrane was developed in ECL Western blotting detection reagents (Amersham Pharmacia Biotech).
Cell killing assay
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay was performed to determine sensitivity to ganciclovir (GCV). Cells maintained in a 25-cm 2 flask with or without the various agents for 2 days, seeded in 96-well plates (6000 cells/well), and incubated in various concentrations of GCV for 5 days. Cell survival was calculated as the percentage of untreated cells.
Results
Preliminary studies demonstrated that the Tg promoter could direct expression of a luciferase gene preferentially in thyroid cancer cells, but the level of activity was deemed insufficient. As shown in Fig. 2 , the endogenous levels of Tg were very low or undetectable in all four cell lines (PCR products detected in FTC 133 and FTC 236 are not clearly visualized in the photograph). However, the knowledge that expression of Tg is a property of differentiated thyrocytes provided the rationale for including a variety of differentiating agents in the experimental design. The goal was to improve the specificity and activity of the constructs. As a first step, we examined the effects of five different agents on the expression of the endogenous Tg gene. Two cell lines were used: FTC 236 and SW-1736. As shown in Fig. 2, 8 -BrcAMP, forskolin, and phenylbutyrate had no effect on the endogenous levels of Tg messenger RNA. However, treatment with either depsipeptide or sodium butyrate, two histone deacetylase inhibitors, resulted in a marked increase in Tg expression. Figure 3 shows the luciferase activity in the four thyroid carcinoma cell lines after transient transfection with either control TK-Luc or the Tg promoter-Luc construct. Luciferase activity in untreated cells was compared with that in cells treated with the five agents evaluated in Fig. 2 . For all cell lines, the luciferase activity of TK-Luc in untreated cells was assigned a value of 100%, and all luciferase activities are expressed relative to this. The induction of luciferase activity correlates well with the effects on the endogenous gene. In agreement with their lack of effect on the expression of the endogenous gene, neither 8-Br-cAMP, forskolin, nor phenylbutyrate had any substantial effect on luciferase activity. In contrast, both depsipeptide and sodium butyrate significantly augmented luciferase activity in all four cell lines, just as they had increased the expression of the endogenous Tg gene. The augmentation achieved with either depsipeptide or sodium butyrate was somewhat more pro-nounced in the two anaplastic cell lines (SW-1736 and KAT-4), in part because their basal level of expression was lower, possibly reflecting their more undifferentiated phenotype.
These results indicated that the promoter activity of both the endogenous gene and the Tg promoter construct could be modulated. However, we sought to develop a construct with a higher specific activity. To achieve this, a second construct was prepared by cloning a putative enhancer element for the Tg gene (19) . Once isolated, it was placed proximal to the Tg promoter, generating a construct designated Tg enhancer/promoter-Luc. Figure 4 shows the results obtained after transient transfection of nine different cell lines. The cell lines used in this experiment include the four thyroid carcinoma cell lines and five cell lines not of thyroid origin. As with the experiments described above, luciferase activity was measured after transient transfections. As in Fig.  3 , for all cell lines the luciferase activity of TK-Luc in untreated cells was assigned a value of 100%, and all luciferase activities are expressed relative to this. The basal activity of this construct was somewhat higher than that of the Tg promoter-Luc construct, a fact obscured by the marked differences in the y-axis between Figs 100%) were as follows: SW-1736, 14.8% vs. 28.6%; KAT-4, 15.1% vs. 32.4%; FTC 133, 32.6% vs. 58.5%; and FTC 236, 34.8% vs. 84.5%. The more striking differences were observed when luciferase activities were measured after treatment with depsipeptide, sodium butyrate, or either of these agents in combination with 8-Br-cAMP. Both depsipeptide and sodium butyrate significantly enhanced the basal activity, and this enhancement was further augmented by the addition of 8-Br- The following cell lines were used: MCF7 (breast), HepG2 (hepatocarcinoma), H295 (adrenocortical), A498 (renal cell), SW620 (colon), SW-1736 and KAT-4 (anaplastic thyroid), and FTC 133 and FTC 236 (follicular thyroid). As in Fig. 3 , for all cell lines the luciferase activity of TK-Luc in untreated cells was assigned a value of 100%, and all luciferase activities are expressed relative to this.
cAMP. This augmentation was not unexpected, as the putative enhancer element alone has been previously shown to be modulated by forskolin and to contain cAMP-like elements (20) . As with the Tg promoter-Luc construct, higher levels were achieved in the more differentiated cell lines (FTC 133 and FTC 236) than the anaplastic cells (SW-1736 and KAT-4). Furthermore, the increases were not explained by differences among the vectors in transfection efficiencies. In FTC133 and SW-1736, cotransfection of the lacZ gene with the Tg promoter-Luc or Tg enhancer/promoter-Luc did not demonstrate significant differences in transfection efficiency (FTC133, 17.0% vs. 13.3%; SW-1736, 25.3% vs. 26.7%) Finally, these studies demonstrated the specificity of the Tg enhancer/promoter-Luc construct, as evidenced by the low to undetectable activity seen in the five cell lines that were not of thyroid origin. Thus, addition of the putative Tg enhancer increased the activity and specificity. The enhanced basal activity and the augmentation by depsipeptide, sodium butyrate, and 8-Br-cAMP in the thyroid carcinoma cells compared with the other cell lines indicated that this construct had a relatively high thyroid cell specificity.
As the eventual goal of these studies is to develop a strategy for the treatment of thyroid cancer in humans, we wanted to examine whether the Tg enhancer/promoter fragment could drive expression of a HSV-TK gene for use in GCV-induced suicide. To do this, the Tg enhancer/promoter sequence was cloned upstream of the HSV-TK gene in an expression vector, and its effects were compared with those of two control vectors: pGL3-TK as a negative control, and TK-TK as a positive control. The latter vector contains the TK gene under the control of the TK promoter, a promoter with activity in all of the cell lines used. Figure 5 shows the results of GCV sensitivity after transient transfections. In the nine cell lines examined, previous studies have found transfection efficiencies of 10 -20%, so that cell killing was probably achieved via a bystander effect (transfection efficiency data not shown). In the four thyroid carcinoma cell lines, no significant cytotoxicity was observed with the pGL-3 negative control. IC 50 values of more than 1000 ng/mL were observed with pGL-3, similar to those with GCV alone (GCV alone data not shown). Some sensitization was observed when cells were transfected with the TK-TK construct. Greater sensitization was observed with the Tg enhancer/promoter-TK vector. In agreement with the results obtained with the luciferase construct, treatment with either depsipeptide or sodium butyrate with 8-Br-cAMP resulted in even greater cytotoxicity. As with the luciferase studies the greatest effect was observed with depsipeptide plus 8-Br-cAMP in combination. With this latter combination, sensitization of as much as 100,000-fold could be achieved, and the maximum effect was most pronounced in the follicular carcinoma cell lines. For comparison, in the four thyroid carcinoma cell lines, cytotoxicity in stable transfectants is shown. The construct used to establish the stable transfectants contains a neomycin resistance gene. The stable transfectants were obtained by exposing cells to increasing concentrations of G418. As all or nearly all stably transfected cells contain the TK gene under the control of the Tg enhancer/promoter, somewhat greater cytotoxicity is observed compared with transiently transfected cells. Finally, in contrast to the results obtained with the thyroid carcinoma cell lines, no enhancement of GCV toxicity was observed with the Tg enhancer/promoter construct in the cell lines not of thyroid origin. Enhanced toxicity was not even observed after treatment with depsipeptide and 8-Br-cAMP. Only with the TK-TK construct was enhanced toxicity found. The similar degrees of enhancement observed with the TK-TK construct in the nine cell lines is indirect evidence of comparable, albeit not identical, transfection efficiencies.
Evidence that treatment with depsipeptide or sodium butyrate enhances GCV toxicity at least in part by increasing TK levels is shown in Fig. 6 . In this experiment stable transfectants were isolated from four thyroid cancer cell lines after transfection with the Tg enhancer/promoter-TK-Neo construct. As expected, expression of HSV-TK protein could not be detected in untransfected parental cells. In contrast, expression could be detected in the Tg enhancer/promoter-TK-Neo stable transfectants. Furthermore, expression of HSV-TK protein could be induced by the agents shown to mediate luciferase expression and GCV cytotoxicity (see Figs. 4 and 5) . Thus, the Tg enhancer/promoter fragment was able to induce expression of HSV-TK (Fig. 6) , and this, in turn, could be used to modulate GCV sensitivity (Fig. 5) .
Discussion
The present study examines potential alternate strategies for the treatment of thyroid cancer. Although surgical resection and radioiodine therapy have been shown to be effective in the therapy of well differentiated thyroid cancers, alternate strategies are needed for patients with poorly differentiated and anaplastic thyroid cancers. We reasoned that a promoter and putative enhancer from a gene expressed specifically in thyroid cells would provide an ideal candidate for a gene therapy strategy. We also surmised that differentiating agents could modulate the expression of thyroidspecific genes and of constructs using promoters from these genes. Our results demonstrate that the Tg promoter and a putative Tg enhancer can direct the expression of luciferase and thymidine kinase in cells of thyroid origin with high specificity. The activity and specificity can be further enhanced by treating cells with the histone deacetylase inhibitors, depsipeptide or sodium butyrate, and with 8-Br-cAMP.
To successfully develop a cancer-specific gene therapy, two requirements must be satisfied: 1) tissue specificity, and 2) sufficient activity to allow therapeutic benefit. The first requirement, specificity, can be achieved if the promoter used restricts expression of the therapeutic gene to tumor cells. To achieve specificity, the Tg promoter appears to be an ideal candidate for thyroid cancer. With the exception of a recent study demonstrating very low levels of expression in the normal kidney (21) , previous studies have demonstrated Tg expression exclusively in normal thyroid tissue and in a majority of thyroid cancers (22) . Furthermore, as demonstrated in the present study, Tg expression can be modulated in cells of thyroid origin, including anaplastic thyroid cells, with depsipeptide or sodium butyrate, two histone deacetylase inhibitors. Luciferase activity and GCV sensitivity were demonstrated in four thyroid carcinoma cells, without significant luciferase activity or GCV sensitivity in five carcinoma cell lines derived from tissues other than the thyroid, including the renal carcinoma cell line, A498. Taken together, these results suggest that the Tg enhancer/ promoter may be valuable as a thyroid-specific construct in a suicide gene therapy strategy. The second requirement, the need for sufficient expression, is essential for successful therapy and impacts the issue of specificity. The level of expression of the Tg promoter in thyroid carcinoma cells was about 20 -35% that of the HSV-TK promoter in the absence of other agents and was 60 -85% after treatment with either sodium butyrate or depsipeptide. Some reports indicate that HSV-TK activity and GCV sensitivity may not be directly correlated to the activity of the promoter driving the HSV-TK gene (23, 24) . However, we believe that the activity of the Tg promoter alone would not be sufficient. To augment the activity of this construct we introduced a putative Tg enhancer proximal to the Tg promoter. With this construct, higher levels of activity were achieved without sacrificing specificity. The augmentation achieved by introducing the putative enhancer was most pronounced after depsipeptide or sodium butyrate treatment, alone or in combination with 8-Br-cAMP, as shown by luciferase activity. This drug-mediated enhancement was not found in the nonthyroid cell lines. Consistent with the results of the luciferase assay, transient transfection of the four thyroid cell lines resulted in much higher sensitivity to GCV, and this sensitivity was augmented further by treatment with depsipeptide or sodium butyrate alone or in combination with 8-Br-cAMP. Enhancement in sensitivity of as much as 100,000-fold was achieved despite low transfection efficiencies, emphasizing the magnitude of this effect. Even greater sensitization may be possible under optional conditions, as shown by the results with the stable transfectants. As with all gene therapy strategies, in vivo toxicities will need to be assessed in preclinical models. Although low levels of expression in normal kidney cells, which do not divide, will probably not result in significant toxicity, attention will be directed to this tissue.
Unlike other tumor-targeted strategies that exploit the expression of genes acquired during malignant transformation, Tg expression is a differentiated function. Tumor dedifferentiation is expected to result in lower expression of Tg and other thyroid markers such as 5Ј-deiodinase, thyroid peroxidase, the TSH receptor, and NIS. Indeed, the inability of poorly differentiated and anaplastic thyroid cancers to trap iodine is thought to be a consequence of a loss of NIS expression. Differentiating agents might up-regulate their transcription. To be sure, the choice of differentiating agent will be important. Our results suggest that histone deacetylase inhibitors may be effective. Histone deacetylase inhibitors have emerged as interesting chemotherapeutic agents, because they affect histone acetylation and, in turn, gene transcription. Numerous studies have demonstrated that histone deacetylases are components of many transcription complexes. The two histone deacetylase inhibitors used in the present study have been tried in patients. Although sodium butyrate is difficult to administer, phase I trials with depsipeptide have found it to be well tolerated, and the levels achieved greatly exceed those used in the present study (our unpublished observations).
In conclusion, we report the construction of a suicide vector with preferential toxicity in thyroid cells. Using the promoter of the Tg gene and a putative enhancer, a construct with high activity and specificity for thyroid cells was constructed. Luciferase and TK expression as well as GCV sensitivity were enhanced by treatment with the histone deacetylase inhibitors, depsipeptide and sodium butyrate, alone or in combination with 8-Br-cAMP. Current efforts are directed at generating a recombinant adenovirus containing the HSV-TK gene under the control of the Tg enhancer/ promoter sequences.
